个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Lin Yu[1,2,3,4] * ; Shen Wenbin[5] * ; Ye Jinjun[6] * ; Luo Honglei[7] * ; Zhang Xizhi[8] * ; Xu Yuanji[1] ; Lin Qin[9] ; Liu Wenyang[10] ; Zhang Yingying[11] ; Xu Yujin[12] ; Jiang Wei[13] ; Zhao Lina[14] ; Liu Anwen[15] ; Wu Lei[16] ; Ge Hong[17] ; Xie Conghua[18] ; Zhao Kuaile[2,3,4] ; Chen Junqiang[19] ; Wang Luhua[20] ; Liu Qi[21,3,4] ;
机构： [1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center Fujian Hospital, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. [2]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. [3]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. [4]Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. [5]Radiotherapy Department of Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [6]Department of Radiotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China. [7]Department of Radiation Oncology, Huai'an First People's Hospital, Huai'an, China. [8]Department of Oncology, The Northern Jiangsu People's Hospital, Yangzhou, China. [9]Department of Radiotherapy, The First Affiliated Hospital of Xiamen University, Xiamen, China. [10]Department of Radiotherapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [11]Department of Oncology, Xiangya Hospital, Central South University, Changsha, China. [12]Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China. [13]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China. [14]Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi'an, China. [15]Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. [16]Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. [17]Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China. [18]Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China. [19]Department of Radiation Oncology, Fudan University Shanghai Cancer Center Fujian Hospital, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, 420 Fuma Road, Jin'an District, Fuzhou 350014, China. [20]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 113 Baohe Road, Longgang District, Shenzhen 518116, China. [21]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai 200032, China.
出处：
DOI： 10.1177/17588359241297092
ISSN：

关键词： esophageal cancer first line pembrolizumab real world squamous cell

摘要：
There are currently limited real-world data on the effectiveness and safety of first-line pembrolizumab combined with chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC) in China. This study was conducted to address this knowledge gap.This multicenter retrospective cohort study was conducted at 17 hospitals in China and included adults (⩾18 years) with stage IV primary ESCC, or recurring 6 months after radical radiotherapy/surgery-based combination therapy, who had received first-line pembrolizumab plus chemotherapy. Data were collected from electronic medical records. Endpoints included objective response rate (ORR), disease control rate (DCR) progression-free survival (PFS), overall survival (OS), and safety. Subgroup analyses were conducted to identify patient characteristics and treatment patterns associated with treatment response.In total, 202 patients who had received treatment from 2018 to 2023 were included: 125 (61.9%) newly diagnosed and 77 (38.1%) with recurrence, 181 (89.1%) were male. Pembrolizumab was most commonly combined with paclitaxel + platinum (69.8%) or fluorouracil + platinum (19.3%). After a median follow-up of 22.6 months (95% confidence interval (CI) 20.1-25.4), the ORR and DCR were 60.9% and 87.6% and the median PFS and OS were 10.8 months (95% CI 9.1-13.5) and 17.3 months (95% CI 14.9-19.9), respectively. OS was similar in patients with treatment-naïve and recurrent disease. Among the combination chemotherapy regimens, paclitaxel + platinum was associated with the longest median OS (18.2 months, 95% CI 16.1-22.5). Favorable survival outcomes were observed in patients with oligometastases. No new safety signals were observed.These real-world data indicate that the first-line treatment with pembrolizumab plus chemotherapy is effective and safe in Chinese patients with advanced ESCC and show that paclitaxel + platinum is the most commonly used and most effective partner chemotherapy in China.© The Author(s), 2024.

基金：
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the National Natural Science Foundation of China (U21A20377, U22A20326, and 82403210).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
第一作者：
第一作者机构： [1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center Fujian Hospital, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. [2]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. [3]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. [4]Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.
共同第一作者：
通讯作者：
通讯机构： [3]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. [4]Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. [21]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai 200032, China.
推荐引用方式(GB/T 7714)：
Lin Yu,Shen Wenbin,Ye Jinjun,et al.Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study[J].Therapeutic Advances In Medical Oncology.2024,16:17588359241297092.doi:10.1177/17588359241297092.
APA：
Lin Yu,Shen Wenbin,Ye Jinjun,Luo Honglei,Zhang Xizhi...&Liu Qi.(2024).Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study.Therapeutic Advances In Medical Oncology,16,
MLA：
Lin Yu,et al."Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study".Therapeutic Advances In Medical Oncology 16.(2024):17588359241297092

相关文献

[1]Immunochemotherapy plus radiotherapy versus immunochemotherapy alone as first-line treatment for treatment-naïve, advanced esophageal squamous cell carcinoma (AEC-ICR-1st): A multi-center cohort study [2]A multicenter, retrospective study analysis: Evaluating the efficacy and safety of pembrolizumab in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma [3]Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China [4]Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis [5]Profiling patient-reported symptom recovery from oesophagectomy for patients with oesophageal squamous cell carcinoma: a real-world longitudinal study [6]Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China. [7]Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations [8]Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma(Open Access) [9]A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Nonsquamous NonSmall Cell Lung Cancer (CTONG1506) [10]食管癌静脉血栓栓塞症发生情况的真实世界研究（附8 458例报告）

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号